DBV Technologies ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.47next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release and Business Update | 28 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly174.9MTarget: Sufficient to fund operations into the third quarter of 2027
Viaskin Peanut BLA Submission Timeline (Children aged 4-7) QuarterlyTarget: Submission in the third quarter of 2026
COMFORT Toddlers Supplemental Safety Study Recruitment Status QuarterlyTarget: Completed recruitment in Q2 2026
Watch Items
- FDA feedback on CMC and biostatistical data formatting for Viaskin Peanut BLATrigger: Any further request for additional clinical data or formatting revisionsAction: Re-evaluate the BLA submission timeline and adjust the cash runway forecast accordingly.
- Cash burn rate and ATM facility utilizationTrigger: Quarterly cash burn exceeding $55 million or failure to raise capital via the refreshed $150 million ATM programAction: Implement stricter cost-containment measures to preserve the runway into Q3 2027.
Research as of 24 Jul 2026